Truist Securities Maintains Hold on Immunovant, Raises Price Target to $30
Benzinga Newsdesk 5 months ago
NewsPrice TargetAnalyst Ratings
Truist Securities analyst Danielle Brill maintains Immunovant (NASDAQ:IMVT) with a Hold and raises the price target from $23 to $30.
Truist Securities analyst Danielle Brill maintains Immunovant (NASDAQ:IMVT) with a Hold and raises the price target from $23 to $30.